Trial Profile

A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared with Open-Label Rivaroxaban in Patients with Atrial Fibrillation (AZALEA)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 01 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Mar 2025 According to an Anthos Therapeutics media release, company will be present these data during the moderated poster sessions from 2:30-4:30pm CT.
29 Mar 2025 According to an Anthos Therapeutics media release, company is presenting two new analyses from its landmark AZALEA-TIMI 71study at the American College of Cardiology Annual Scientific Session (ACC.25)
22 Jan 2025 According to an Anthos Therapeutics media release, results from this study were published in the January 23 issue of the New England Journal of Medicine (NEJM).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com